AcuCort plans rights issue of up to SEK 70.3 million to fund Zeqmelit FDA push

• AcuCort’s board resolved to launch a rights issue of up to 78,148,177 units, aiming to raise about SEK 70.3 million initially.
• Units priced at SEK 0.90 include three shares and two TO 3 warrants; TO 3 could add up to SEK 93.8 million.
• Funding package includes about SEK 52.8 million in subscription undertakings and underwriting commitments, covering roughly 75% of the issue.
• A SEK 5 million bridge loan was raised to cover funding needs until completion; the rights issue awaits shareholder approval on Nov. 5, 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AcuCort AB published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.